{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:40:30Z","timestamp":1782474030761,"version":"3.54.5"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH062646"],"award-info":[{"award-number":["MH062646"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disease and Stroke","doi-asserted-by":"publisher","award":["NS031373"],"award-info":[{"award-number":["NS031373"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH institutional training grant","doi-asserted-by":"publisher","award":["T32 MH065215-14"],"award-info":[{"award-number":["T32 MH065215-14"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.neuropharm.2017.09.012","type":"journal-article","created":{"date-parts":[[2017,9,9]],"date-time":"2017-09-09T08:49:09Z","timestamp":1504946949000},"page":"438-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"PC","title":["Positive allosteric modulation of M 1 and M 4 muscarinic receptors as potential therapeutic treatments for schizophrenia"],"prefix":"10.1016","volume":"136","author":[{"given":"Samantha E.","family":"Yohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jeffrey","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.09.012_bib176","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib177","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.115.226910","article-title":"Evidence for classical cholinergic toxicity associated with selective activation of M1 muscarinic receptors","volume":"356","author":"Alt","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.npp.1301208","article-title":"Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor","volume":"32","author":"Barak","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1017\/S1461145708009176","article-title":"Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs","volume":"12","author":"Barak","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145710001549","article-title":"The M(1)\/M(4) preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia","volume":"14","author":"Barak","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0166-2236(92)90049-E","article-title":"Protein kinase C modulation of NMDA currents: an important link for LTP induction","volume":"15","author":"Ben-Ari","year":"1992","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1006\/mcne.2001.1042","article-title":"M1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices","volume":"18","author":"Berkeley","year":"2001","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0074-7742(06)78007-2","article-title":"Cholinergic circuits and signaling in the pathophysiology of schizophrenia","volume":"78","author":"Berman","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0006-8993(82)90809-5","article-title":"Responses of intracellularly recorded cortical neurons to the iontophoretic application of dopamine","volume":"245","author":"Bernardi","year":"1982","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jphysparis.2013.04.003","article-title":"The effect of non-competitive NMDA receptor antagonist MK-801 on neuronal activity in rodent prefrontal cortex: an animal model for cognitive symptoms of schizophrenia","volume":"107","author":"Blot","year":"2013","journal-title":"J.\u00a0Physiol. Paris"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib11","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/cercor\/bht329","article-title":"Modulation of hippocampus-prefonrtal cortex synaptic transmission and disruption of executive cognitive functions by MK-801","volume":"25","author":"Blot","year":"2015","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"issue":"Suppl.\u00a04","key":"10.1016\/j.neuropharm.2017.09.012_bib13","first-page":"S16","article-title":"The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease","volume":"11","author":"Bodick","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","article-title":"The cholinergic system and Parkinson disease","volume":"221","author":"Bohnen","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.3037705","article-title":"Identification of a family of muscarinic acetylcholine receptor genes","volume":"237","author":"Bonner","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0896-6273(88)90190-0","article-title":"Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes","volume":"1","author":"Bonner","year":"1988","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1124\/jpet.108.140350","article-title":"Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats","volume":"327","author":"Brady","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1358\/dnp.2010.23.4.1416977","article-title":"The antipsychotic potential of muscarinic allosteric modulation","volume":"23","author":"Bridges","year":"2010","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pnpbp.2013.11.008","article-title":"Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically","volume":"49","author":"Brown","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1021\/cn500128b","article-title":"Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents","volume":"5","author":"Bubser","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.neuron.2010.11.018","article-title":"Facilitation of long-term potentiation by muscarinic M(1) receptors is mediated by inhibition of SK channels","volume":"68","author":"Buchanan","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib22","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1460-9568.2003.02588.x","article-title":"Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in\u00a0vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity","volume":"17","author":"Bymaster","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0014-2999(98)00487-7","article-title":"Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane","volume":"356","author":"Bymaster","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib24","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/npp.2014.2","article-title":"Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100","volume":"39","author":"Byun","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib25","doi-asserted-by":"crossref","first-page":"18464","DOI":"10.1523\/JNEUROSCI.4719-11.2011","article-title":"Induction of activity-dependent LTD requires muscarinic receptor activation in medial prefrontal cortex","volume":"31","author":"Caruana","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","article-title":"Muscarinic receptors\u2013characterization, coupling and function","volume":"58","author":"Caulfield","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2012.10.011","article-title":"Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication","volume":"697","author":"Chambon","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib28","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1073\/pnas.0800567105","article-title":"Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia","volume":"105","author":"Chan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1124\/jpet.116.235788","article-title":"Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior","volume":"359","author":"Choy","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nrd746","article-title":"Allosteric binding sites on cell-surface receptors: novel targets for drug discovery","volume":"1","author":"Christopoulos","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.tips.2008.12.002","article-title":"Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib33","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nrd4308","article-title":"Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders","volume":"13","author":"Conn","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib34","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","article-title":"Inverted-U-shaped dopamine actions on human working memory and cognitive control","volume":"69","author":"Cools","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0006-3223(00)00918-5","article-title":"Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation","volume":"48","author":"Crook","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib36","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.158.6.918","article-title":"Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment","volume":"158","author":"Crook","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.pscychresns.2015.09.004","article-title":"The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia","volume":"234","author":"Cropley","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0006-8993(94)90017-5","article-title":"Involvement of M1 muscarinic receptors in the initiation of cholinergically induced epileptic seizures in the rat brain","volume":"643","author":"Cruickshank","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib39","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1021\/acs.jmedchem.6b00544","article-title":"Discovery of the potent and selective M1 PAM-agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)ben zyl]pyridine-2-carboxamide (PF-06767832): evaluation of efficacy and cholinergic side effects","volume":"59","author":"Davoren","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib40","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","article-title":"Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"7","author":"Dean","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib198","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/1566524033479654","article-title":"Muscarinic receptors in schizophrenia","volume":"3","author":"Dean","year":"2003","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.schres.2008.08.003","article-title":"Levels of [(3)H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1","volume":"106","author":"Dean","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1021\/cn200110q","article-title":"Muscarinic acetylcholine receptor subtypes as potential drug targets for the treatment of schizophrenia, drug abuse and Parkinson's disease","volume":"3","author":"Dencker","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib43","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1523\/JNEUROSCI.0370-11.2011","article-title":"Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1\/M4 preferring muscarinic receptor agonist xanomeline","volume":"31","author":"Dencker","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib44","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1039\/c002938f","article-title":"Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders","volume":"6","author":"Digby","year":"2010","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tips.2014.12.002","article-title":"Nicotinic ACh receptors as therapeutic targets in CNS disorders","volume":"36","author":"Dineley","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib179","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00213-004-2109-y","article-title":"Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia","volume":"179","author":"Egerton","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib178","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-23274-9_1","article-title":"Overview of muscarinic receptor subtypes","volume":"208","author":"Eglen","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1096\/fasebj.9.8.7768353","article-title":"Muscarinic acetylcholine receptors: signal transduction through multiple effectors","volume":"9","author":"Felder","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib47","first-page":"369","article-title":"Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy","volume":"31","author":"Ferreri","year":"2006","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib48","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0024-3205(95)00022-X","article-title":"Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies","volume":"56","author":"Flynn","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib49","first-page":"183","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia","volume":"10","author":"Foster","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib50","first-page":"413","article-title":"Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling","volume":"14","author":"Foster","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib51","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neuron.2017.03.016","article-title":"Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders","volume":"94","author":"Foster","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3758\/CABN.1.2.137","article-title":"Interactions between frontal cortex and basal ganglia in working memory: a computational model","volume":"1","author":"Frank","year":"2001","journal-title":"Cogn. Affect Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-3223(01)01342-7","article-title":"A\u00a0double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia","volume":"51","author":"Friedman","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib55","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/FBP.0000000000000003","article-title":"MK-801-induced and scopolamine-induced hyperactivity in rats neonatally treated chronically with MK-801","volume":"24","author":"Furuie","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000357682","article-title":"Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats","volume":"93","author":"Galloway","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib57","doi-asserted-by":"crossref","first-page":"15312","DOI":"10.1073\/pnas.261583798","article-title":"Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice","volume":"98","author":"Gerber","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00421473","article-title":"Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients","volume":"40","author":"Gerlach","year":"1975","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2217\/fnl.14.63","article-title":"The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia","volume":"10","author":"Ghoshal","year":"2015","journal-title":"Future Neurol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib61","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model","volume":"41","author":"Ghoshal","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib62","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/S0024-3205(01)01039-6","article-title":"Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice","volume":"68","author":"Gomeza","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib63","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1021\/acschemneuro.5b00123","article-title":"Role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice","volume":"6","author":"Gould","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib180","article-title":"Conigitive enhancement and antipsSSychotic-like activity following repeated dosing with the selective M4 Pam VU0467154","author":"Gould","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib64","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1021\/acschemneuro.6b00230","article-title":"Prefrontal cortex-mediated impairments in a genetic model of NMDA receptor hypofunction are reversed by the novel M1 PAM VU6004256","volume":"7","author":"Grannan","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib66","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/schbul\/sbi035","article-title":"Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy","volume":"31","author":"Greenwood","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(06)78001-1","article-title":"Neurobiology of dopamine in schizophrenia","volume":"78","author":"Guillin","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib68","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0306-4522(99)00395-4","article-title":"Integrity of the mesocortical dopaminergic system is necessary for complete expression of in\u00a0vivo hippocampal-prefrontal cortex long-term potentiation","volume":"94","author":"Gurden","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib69","doi-asserted-by":"crossref","first-page":"15850","DOI":"10.1074\/jbc.M011563200","article-title":"The M1 receptor is required for muscarinic activation of mitogen-activated protein (MAP) kinase in murine cerebral cortical neurons","volume":"276","author":"Hamilton","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib70","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1523\/JNEUROSCI.14-05-03351.1994","article-title":"Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies","volume":"14","author":"Hersch","year":"1994","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib71","doi-asserted-by":"crossref","first-page":"24697","DOI":"10.1074\/jbc.M703580200","article-title":"Structure of inhibited fructose-1,6-bisphosphatase from Escherichia coli: distinct allosteric inhibition sites for AMP and glucose 6-phosphate and the characterization of a gluconeogenic switch","volume":"34","author":"Hines","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib72","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib73","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.2174\/138161209788957528","article-title":"Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging","volume":"15","author":"Howes","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<357::AID-SYN9>3.0.CO;2-B","article-title":"Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons","volume":"27","author":"Ince","year":"1997","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib75","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1176\/ajp.130.12.1370","article-title":"Antagonistic effects of physostigmine and methylphenidate in man","volume":"12","author":"Janowsky","year":"1973","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib76","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1097\/00001756-199510020-00006","article-title":"Inhibition of hippocampoprefrontal cortex excitatory responses by the mesocortical DA system","volume":"6","author":"Jay","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib77","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1523\/JNEUROSCI.3843-09.2010","article-title":"A\u00a0subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors","volume":"30","author":"Jeon","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib78","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S0033291700047942","article-title":"Adverse effects of anticholinergic medication on positive schizophrenic symptoms","volume":"13","author":"Johnstone","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/npp.2011.199","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia","volume":"37","author":"Jones","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib80","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.104.075887","article-title":"Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats","volume":"312","author":"Jones","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib81","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-2999(00)00055-8","article-title":"Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats","volume":"391","author":"Jones","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib181","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib182","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pnpbp.2007.09.008","article-title":"Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study","volume":"32","author":"Kalinichev","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib82","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-016-2175-4","article-title":"Modulatory effects of \u03b17 nAChRs on the immune system and its relevance for CNS disorders","volume":"73","author":"Kalkman","year":"2016","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib83","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-6606-5-10","article-title":"M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition","volume":"5","author":"Koshimizu","year":"2012","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib84","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd4295","article-title":"Muscarinic acetylcholine receptors: novel opportunities for drug development","volume":"13","author":"Kruse","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib85","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.3390\/ijms16036447","article-title":"Cholinergic transactivation of the EGFR in HaCaT keratinocytes stimulates a flotillin-1 dependent MAPK-mediated transcriptional response","volume":"16","author":"Kuhne","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.brainres.2009.05.004","article-title":"Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors","volume":"1279","author":"Kunitachi","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib87","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.115.226712","article-title":"The M1 muscarinic positive allosteric modulator PQCA improvesperformance on translatable tests of memory and attention in rhesus monkeys","volume":"355","author":"Lange","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib88","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1196\/annals.1300.063","article-title":"Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment","volume":"1003","author":"Laruelle","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib89","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/npp.2009.194","article-title":"Molecular mechanisms of action and in\u00a0vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties","volume":"35","author":"Leach","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib90","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","article-title":"Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies","volume":"11","author":"Levey","year":"1991","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib91","first-page":"810548","article-title":"Hipocampal-prefonrtal circuit and disrupted functional connectivity in psychiatric and neurodegenerative disorders","author":"Li","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib92","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2007.06.025","article-title":"AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus","volume":"572","author":"Li","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2008.08.009","article-title":"Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine","volume":"596","author":"Li","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib94","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1016\/S0021-9258(18)83237-9","article-title":"Molecular cloning and expression of a fifth muscarinic acetylcholine receptor","volume":"264","author":"Liao","year":"1989","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000072880","article-title":"Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients","volume":"48","author":"Liao","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib96","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1021\/acs.chemrev.5b00656","article-title":"Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors","volume":"116","author":"Lindsley","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib97","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2017.01.001","article-title":"Recent advances in drug discovery of GPCR allosteric modulators for neurodegenerative disorders","volume":"32","author":"Lutjens","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib98","doi-asserted-by":"crossref","first-page":"15950","DOI":"10.1073\/pnas.0900903106","article-title":"Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation","volume":"106","author":"Ma","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib99","first-page":"398","article-title":"Animal models of schizophrenia: a critical review","volume":"26","author":"Marcotte","year":"2001","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib100","doi-asserted-by":"crossref","first-page":"11465","DOI":"10.1073\/pnas.95.19.11465","article-title":"Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells","volume":"95","author":"Marino","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib101","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/mol.108.052886","article-title":"Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity","volume":"75","author":"Marlo","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib102","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/cercor\/bhv031","article-title":"Age-dependent long-term potentiation deficits in the prefrontal cortex of the Fmr1 knockout mouse model of fragile X syndrome","volume":"26","author":"Martin","year":"2016","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib103","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0074-7742(06)78008-4","article-title":"Schizophrenia and the alpha7 nicotinic acetylcholine receptor","volume":"78","author":"Martin","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric modulation of G protein-coupled receptors","volume":"47","author":"May","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"Suppl.\u00a0l","key":"10.1016\/j.neuropharm.2017.09.012_bib105","first-page":"20","article-title":"A\u00a0double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function","volume":"48","author":"McEvoy","year":"1987","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib106","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/09540260701502468","article-title":"The role of dopamine for the pathophysiology of schizophrenia","volume":"19","author":"Meisenzahl","year":"2007","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib107","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib108","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","article-title":"Cholinergic system during the progression of Alzheimer's disease: therapeutic implications","volume":"8","author":"Mufson","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib109","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1196\/annals.1377.003","article-title":"Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine","volume":"1086","author":"Nabeshima","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib183","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/070674377702200604","article-title":"Dopamine and schizophrenia. A reappraisal in the ligh of clinical studies with clozapine","volume":"22","author":"Nair","year":"1977","journal-title":"Can. Psychiatr. Assoc. J."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib110","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"10","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib111","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.nbd.2013.09.013","article-title":"Development of allosteric modulators of GPCRs for treatment of CNS disorders","volume":"61","author":"Nickols","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib112","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1046\/j.1460-9568.2003.02549.x","article-title":"Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence","volume":"17","author":"Ninan","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib113","doi-asserted-by":"crossref","first-page":"21433","DOI":"10.3390\/ijms151121433","article-title":"Epidermal growth factor receptor transactivation is required for mitogen-activated protein kinase activation by muscarinic acetylcholine receptors in HaCaT keratinocytes","volume":"15","author":"Ockenga","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib114","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0893-133X(98)00048-7","article-title":"Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells","volume":"20","author":"Olianas","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-3-642-25758-2_8","article-title":"Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the \u03b17 nicotinic receptor","volume":"213","author":"Olincy","year":"2013","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib116","doi-asserted-by":"crossref","first-page":"14078","DOI":"10.1073\/pnas.1512812112","article-title":"Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice","volume":"112","author":"Pancani","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib117","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2008.09.025","article-title":"Weight effects associated with antipsychotics: a comprehensive database analysis","volume":"110","author":"Parsons","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib118","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1523\/JNEUROSCI.22-07-02541.2002","article-title":"Nictonic acetycholine receptors interac with dopamine in induction of striatal long-term depression","volume":"22","author":"Partridge","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib184","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0006-3223(99)00148-1","article-title":"Impaired prepulse inhibition of acoustic startle in schizophrenia","volume":"47","author":"Parwani","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib189","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"PT"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib119","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.neuroscience.2009.10.056","article-title":"CaV2.1 channels are modulated by muscarinic M1 receptors through phosphoinositide hydrolysis in neostriatal neurons","volume":"165","author":"Perez-Burgos","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib120","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/brcg.1995.1255","article-title":"Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness","volume":"28","author":"Perry","year":"1995","journal-title":"Brain Cogn."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib121","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1176\/appi.ajp.158.7.1058","article-title":"Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain","volume":"7","author":"Perry","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib122","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0006-3223(00)01017-9","article-title":"The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex","volume":"49","author":"Perry","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib123","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","article-title":"Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior","volume":"76","author":"Picciotto","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib124","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1192\/bjp.140.5.470","article-title":"Anti-cholinergic drugs and memory: the effects of benzhexol on memory in a group of geriatric patients","volume":"140","author":"Potamianos","year":"1982","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib125","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3649","article-title":"Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap","volume":"7","author":"Pratt","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib126","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","article-title":"Towards a muscarinic hypothesis of schizophrenia","volume":"12","author":"Raedler","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib127","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.160.1.118","article-title":"In\u00a0vivo determination of muscarinic acetylcholine receptor availability in schizophrenia","volume":"160","author":"Raedler","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11530260-000000000-00000","article-title":"Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature","volume":"24","author":"Ribeiz","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib129","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1185\/030079904125004060","article-title":"Nicotinic receptors and schizophrenia","volume":"20","author":"Ripoll","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib130","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/acschemneuro.6b00429","article-title":"Diverse effects on M1 signaling and adverse effect liability within a series of M1 ago-PAMs","volume":"4","author":"Rook","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib131","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002826-200209000-00010","article-title":"Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia","volume":"25","author":"Rosse","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib132","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib186","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-004-1810-1","article-title":"Apomorphine-induced disruption of prepulse inhibition that can be normalised by system haloperidol is insensitve to clozapine treatment","volume":"175","author":"Russig","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00008877-199501000-00009","article-title":"Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats","volume":"6","author":"Sams-Dodd","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib133","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0006-8993(00)03170-X","article-title":"Biotinylated m4-toxin demonstrates more M4 muscarinic receptor protein on direct than indirect striatal projection neurons","volume":"894","author":"Santiago","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib134","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/mp.2008.28","article-title":"Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia","volume":"14","author":"Scarr","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib135","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1038\/tp.2013.3","article-title":"Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA","volume":"3","author":"Scarr","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib136","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2008.05711.x","article-title":"Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?","volume":"107","author":"Scarr","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib137","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/14737175.9.1.73","article-title":"Role of the cholinergic system in the pathology and treatment of schizophrenia","volume":"9","author":"Scarr","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib138","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.schres.2013.01.023","article-title":"Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia","volume":"146","author":"Scarr","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib139","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1523\/JNEUROSCI.5058-06.2008","article-title":"Coactivation of M(1) muscarinic and alpha1 adrenergic receptors stimulates extracellular signal-regulated protein kinase and induces long-term depression at CA3-CA1 synapses in rat hippocampus","volume":"28","author":"Scheiderer","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.avb.2008.06.003","article-title":"Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders","volume":"13","author":"Seo","year":"2008","journal-title":"Aggress. Violent Behav."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib141","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0022-3565(24)34979-1","article-title":"Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats","volume":"290","author":"Shannon","year":"1999","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib142","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0920-9964(99)00138-3","article-title":"Xanomeline, an M(1)\/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice","volume":"42","author":"Shannon","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib143","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib144","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0022-510X(01)00638-4","article-title":"Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies: an immunohistochemical study","volume":"193","author":"Shiozaki","year":"2001","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib145","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A\u00a0selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib146","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nchembio.2007.55","article-title":"An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission","volume":"4","author":"Shirey","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib147","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S0033291700012964","article-title":"Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping","volume":"17","author":"Singh","year":"1987","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib148","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib149","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2045125314557797","article-title":"Drug models of schizophrenia","volume":"5","author":"Steeds","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib150","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1176\/ajp.150.5.752","article-title":"Comorbidity in psychosis at first hospitalization","volume":"150","author":"Strakowski","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib151","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1176\/appi.ajp.157.10.1552","article-title":"Genetic epidemiology of major depression: review and meta-analysis","volume":"157","author":"Sullivan","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib152","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1476-5381.2010.01184.x","article-title":"Impact of species variability and 'probe-dependence' on the detection and in\u00a0vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor","volume":"162","author":"Suratman","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib153","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1176\/ajp.152.5.814","article-title":"Treatment of schizophrenia with anticholinergic medications","volume":"152","author":"Tandon","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib154","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/archpsyc.1989.01810080075010","article-title":"Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic\/dopaminergic interactions in schizophrenia","volume":"46","author":"Tandon","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0920-9964(91)90006-D","article-title":"Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms","volume":"4","author":"Tandon","year":"1991","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib156","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/13543784.2013.750650","article-title":"Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia","volume":"22","author":"Thakurathi","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib157","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1523\/JNEUROSCI.1395-14.2014","article-title":"Early adolescent MK-801 exposure impairs the maturation of ventral hippocampal control of basolateral amygdala drive in the adult prefrontal cortex","volume":"34","author":"Thomases","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib158","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00213-009-1740-z","article-title":"Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice","volume":"208","author":"Thomsen","year":"2010","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib159","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","article-title":"M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies","volume":"18","author":"Tzavara","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib160","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","article-title":"Side effects of atypical antipsychotics: a brief overview","volume":"7","author":"Ucok","year":"2008","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib161","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00002093-199812000-00010","article-title":"Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB)","volume":"12","author":"Veroff","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib162","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.neuropharm.2011.11.024","article-title":"Prolonged exposure to NMDAR antagonist induced cell-type specific changes of glutamatergic receptors in rat prefrontal cortex","volume":"62","author":"Wang","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib163","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.neuropharm.2006.12.007","article-title":"Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model","volume":"52","author":"Wang","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib164","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/npp.2013.186","article-title":"The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype","volume":"38","author":"Watt","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-pharmtox-010611-134525","article-title":"Drugs for allosteric sites on receptors","volume":"54","author":"Wenthur","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib166","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.pharmtox.44.101802.121622","article-title":"Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications","volume":"44","author":"Wess","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib167","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/acsmedchemlett.6b00461","article-title":"Discovery of VU0467485\/AZ13713945: an M4 PAM evaluated as a preclinical candidate for the treatment of schizophrenia","volume":"8","author":"Wood","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib168","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1016\/j.bmcl.2016.07.042","article-title":"Challenges in the development of an M4 PAM in\u00a0vivo tool compound: the discovery of VU0467154 and unexpected DMPK profiles of close analogs","volume":"26","author":"Wood","year":"2017","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib169","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","article-title":"Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice","volume":"603","author":"Woolley","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib170","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrd4052","article-title":"Emerging paradigms in GPCR allostery: implications for drug discovery","volume":"12","author":"Wotten","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib171","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0306-4522(01)00039-2","article-title":"Coordinated expression of muscarinic receptor messenger RNAs in striatal medium spiny neurons","volume":"103","author":"Yan","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib187","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/B978-0-12-394596-9.00012-3","article-title":"Animal models of schizophrenia emphasizing construct validity","volume":"105","author":"Yanagi","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib172","first-page":"3","article-title":"Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia","volume":"12","author":"Yeomans","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib173","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1113\/jphysiol.2014.275453","article-title":"Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: roles in cellular excitability, inhibitory transmission and cognition","volume":"592","author":"Yi","year":"2014","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib188","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1034\/j.1601-183X.2003.00041.x","article-title":"Bioinformatic analysis of autism positional candidate genes using biological databases and computational gene network prediction","volume":"5","author":"Yonan","year":"2003","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuropharm.2017.09.012_bib174","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.npp.1300367","article-title":"Investigation of m1\/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder","volume":"29","author":"Zavitsanou","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.012_bib175","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1523\/JNEUROSCI.22-05-01709.2002","article-title":"Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice","volume":"22","author":"Zhang","year":"2002","journal-title":"J.\u00a0Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730429X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730429X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T17:14:57Z","timestamp":1750871697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081730429X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":189,"alternative-id":["S002839081730429X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}